About us Contacts Drug interactions: 390 212
Drug search by name

Darunavir Tablets and Korlym

Determining the interaction of Darunavir Tablets and Korlym and the possibility of their joint administration.

Check result:
Darunavir Tablets <> Korlym
Relevance: 17.05.2023 Reviewer: Shkutko P.M., M.D., in

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer:

Using miFEPRIStone together with darunavir may increase the blood levels and effects of both medications. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications, particularly if you are on miFEPRIStone for a prolonged period. Contact your doctor if your condition changes or you experience increased side effects. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Professional:

MONITOR: Coadministration of mifepristone with a drug that is both a substrate as well as inhibitor of CYP450 3A4 may result in increased plasma concentrations of both drugs. Mifepristone itself is also a substrate and moderate inhibitor of CYP450 3A4. Theoretically, competitive and/or noncompetitive metabolic inhibition may occur. Because mifepristone is associated with dose-dependent prolongation of the QT interval, increased levels may potentiate the risk of ventricular arrhythmias such as torsade de pointes and sudden death.

MANAGEMENT: Due to its potent antiglucocorticoid effects and potential to cause dose-related prolongation of the QT interval, caution is advised if mifepristone is prescribed in combination with a CYP450 3A4 inhibitor, particularly when used daily to control hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome. When the coadministered drug is also a CYP450 3A4 substrate, clinical and/or laboratory monitoring may be appropriate following the addition or withdrawal of mifepristone, and the dosage adjusted as necessary. Because mifepristone is eliminated slowly from the body, drug interactions may be observed for a prolonged period following discontinuation (approximately 2 to 3 weeks if mifepristone had been administered chronically to steady state).

References
  • "Product Information. Mifeprex (mifepristone)" Danco Laboratories, New York, NY.
  • "Product Information. Korlym (mifepristone)." Corcept Therapeutics Incorporated, Menlo Park, CA.
Darunavir Tablets

Generic Name: darunavir

Brand name: Prezista

Synonyms: Darunavir

Korlym

Generic Name: mifepristone

Brand name: Korlym, Mifeprex

Synonyms: n.a.

In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.

Interaction with food and lifestyle
Disease interaction